Tag Archive for: pre-treated hormone receptor positive/HER2 negative metastatic breast cancer

Gilead Sciences Inc.’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.